NR2F6 and neoplasm: Consistent with tumor growth inhibition seen upon NR2F6 loss, both pathway and upstream regulator analyses of differentially expressed genes (DEGs) identified activation of antitumor immune signaling only in vivo (in bulk tumor and sorted tumor cell samples).